Chen Man, Fu Minjing, Gong Meiwei, Gao Yajing, Wang Aixian, Zhao Wei, Wu Xueying, Wang Hui
Department of Laboratory Medicine, Hebei Yanda Ludaopei Hospital, Sanhe, Langfang, Hebei, China.
Department of Laboratory Medicine, Beijing Ludaopei Hospital, Beijing, China.
Open Med (Wars). 2023 Jul 25;18(1):20230745. doi: 10.1515/med-2023-0745. eCollection 2023.
Full spectrum flow cytometry brings a breakthrough for minimal residual disease (MRD) detection in acute myeloid leukemia (AML). We aimed to explore the role of a new panel in MRD detection. We established a 24-color full-spectrum flow cytometry panel. A tube of 24-color antibodies included CD45, CD117, CD34, HLA-DR, CD15, CD64, CD14, CD11c, CD11b, CD13, CD33, CD371, CD7, CD56, CD19, CD4, CD2, CD123, CD200, CD38, CD96, CD71, CD36, and CD9. We discovered that when a tube meets 26 parameters (24 colors), these markers were not only limited to the observation of MRD in AML, but also could be used for fine clustering of bone marrow cells. Mast cells, basophils, myeloid dendritic cells, and plasmacoid dendritic cells were more clearly observed. In addition, immune checkpoint CD96 had the higher expression in CD117+ myeloid naive cells and CD56dimNK cells, while had the lower expression in CD56briNK cells in AML-MRD samples than in normal bone marrow samples. CD200 expression was remarkably enhanced in CD117+ myeloid naive cells, CD4+ T cells, T cells, activated T cells, CD56dimNK cells, and CD56briNK cells in AML-MRD samples. Our results can be used as important basis for auxiliary diagnosis, prognosis judgment, treatment guidance, and immune regulation in AML.
全谱流式细胞术为急性髓系白血病（AML）微小残留病（MRD）检测带来了突破。我们旨在探索一种新的检测组合在MRD检测中的作用。我们建立了一个24色全谱流式细胞术检测组合。一管24色抗体包括CD45、CD117、CD34、HLA-DR、CD15、CD64、CD14、CD11c、CD11b、CD13、CD33、CD371、CD7、CD56、CD19、CD4、CD2、CD123、CD200、CD38、CD96、CD71、CD36和CD9。我们发现，当一管满足26个参数（24种颜色）时，这些标志物不仅限于观察AML中的MRD，还可用于骨髓细胞的精细聚类。肥大细胞、嗜碱性粒细胞、髓样树突状细胞和浆细胞样树突状细胞能更清晰地被观察到。此外，免疫检查点CD96在AML-MRD样本中的CD117+髓系幼稚细胞和CD56dimNK细胞中表达较高，而在AML-MRD样本中CD56briNK细胞中的表达低于正常骨髓样本。CD200在AML-MRD样本中的CD117+髓系幼稚细胞、CD + T细胞、T细胞、活化T细胞、CD56dimNK细胞和CD56briNK细胞中表达显著增强。我们的结果可作为AML辅助诊断、预后判断、治疗指导和免疫调节的重要依据。
